Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code：2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE THIRD QUARTER OF 2026

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the "**Company**" or "**Genertec Universal Medical**"), together with its subsidiaries (the "**Group**"), for the third quarter ended 30 September 2026.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first three quarters of 2026, the Group maintained its strategic focus amid multiple pressures, deepened the transformation of its finance business, steadily enhanced its medical service capabilities, and maintained steady progress and improved quality in its overall operations. For the nine months ended 30 September 2026, the consolidated revenue of the Group decreased by approximately 5.8% as compared with the corresponding period of 2025, primarily due to the transformation of the finance business, with the profit for the period increased by approximately 0.2% as compared with the corresponding period of 2025, mainly attributable to the optimization of overall funding cost control and the reduction in costs related to the healthcare business, while the profit for the period attributable to owners of the parent increased by approximately 1.2% as compared with the corresponding period of 2025.

In respect of integrated healthcare business, the Group proactively responded to healthcare payment reforms, continuously strengthened the development of "Integration, Differentiation, Specialization, Digitalization and Optimization", and steadily advanced the capability building of "Discipline Building, Scientific Research and Innovation, Talent Cultivation, Environment and Services Improvement". The medical institutions affiliated with the Group performed well in the first three quarters of 2026: achieving positive results in discipline capability building, with 4 provincial-level key specialties added, bringing the total to 26, and 5 municipal-level key specialties added, bringing

the total to 117; vigorously developing therapeutic outpatient services and non-medical insurance businesses, and deeply implementing all-year-round non-stop clinics, extended-hour clinics and specialist clinics, with outpatient and emergency visits reaching 7.477 million, representing an increase of 7.5% year-on-year and therapeutic outpatient revenue increasing by 3.5% year-on-year; solidly advancing special surgical initiatives, with the surgical mix continuing to optimize and the proportion of Grade III and Grade IV surgeries increasing by 2.4 percentage points; deepening standardized diagnosis and treatment by disease type, with the business mix continuing to improve and the proportion of effective revenue increasing by 2.3 percentage points year-on-year. The risk resistance and sustainable development capabilities of medical institutions were steadily enhanced.

In respect of specialised medical care and healthcare technology, the Group adheres to the "dual-wheel drive" of internal development and external expansion, cultivating its specialty businesses and core competencies. Currently, this segment has made continuous progress in areas such as business layout expansion and capability building. Among them, its subsidiary Genertec Universal Medical Technology Services (Tianjin) Co., Ltd. ("**Universal Technology Services**"), with years of practical experience, became a member of the editorial committee of the Blue Book of Medical Devices: China Medical Device Industry Development Report (2026); its management case "Innovative Practices and Measures for Full Life Cycle Management of Medical Equipment Assets" was successfully selected for the Practice section of the Blue Book, further enhancing its industry influence. Its subsidiary Genertec Universal Jadebird Health Technology Co., Ltd. ("**Universal Jadebird**") newly added 6 integrated medical and elderly care institutions to its offline operations in the first three quarters of 2026, with a net increase of 746 nursing care beds, bringing the total to 4,257, and 1,880 newly built and operated home-based elderly care beds, bringing the total to 75,009, continuously expanding its business layout. In addition, the Group continued to advance its health digital and intelligent technology business. Its digital and intelligent project "Construction of a Smart Hospital Platform Empowered by AI Across All Scenarios and Processes" won first prize in the ICT China (2026) Case Selection hosted by the China Association of Communications Enterprises, creating a replicable and scalable practical model for the digital transformation of central state-owned enterprise hospitals.

In respect of finance business, the Group continues to focus on business areas such as medical health and elder care, equipment manufacturing, chemicals and pharmaceuticals, and specialty industries, solidly advancing the planning and implementation of the transformation and upgrading of the finance business, and actively exploring new models of industry-finance integration, including "finance lease + life cycle management of medical equipment", "finance lease + elderly care operations", "finance lease + supply chain finance", and "finance lease + technology introduction + operations", so as to serve the modern industrial system and the core responsibilities and main businesses of central state-owned enterprises with financial strength. In the first three quarters of 2026, disbursements to industrial projects such as equipment manufacturing, chemicals and pharmaceuticals increased significantly; the proportion of disbursements serving core businesses increased from 12.8% in the corresponding period of last year to 44.0%, indicating a clear improvement in the disbursement mix. As at 30 September 2026, the Group's total interest-earning assets slightly decreased compared with the beginning of 2026, while net interest margin and net interest spread remained stable compared with the corresponding period of last year. Asset quality remained stable and controllable overall, and provision coverage remained prudent.

The Company hereby reminds investors that the above unaudited operation summary for the third quarter ended 30 September 2026 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 29 October 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Xia Qi and Ms. Wang Lin; the non-executive directors of the Company are Mr. Tong Chaoyin, Mr. Lin Chunhai, Mr. Huang Youjie and Mr. Ma Wanming; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.